¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"serum response factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • serum hepatitis
    Ç÷û°£¿°
  • serum imbibition
    Ç÷ûÈí¼ö
  • serum intoxication
    Ç÷ûÁßµ¶
  • serum rash
    Ç÷û¹ßÁø
  • serum separator tube
    Ç÷ûºÐ¸®°ü
  • serum shock
    Ç÷û¼îÅ©
  • serum sickness
    Ç÷ûº´
  • serum urea nitrogen/creatinine ratio
    Ç÷û¿ä¼ÒÁú¼Ò/Å©·¹¾ÆÆ¼´Ñºñ
  • serum-fast
    Ç÷ûÀúÇ×¼º-
  • arousal response
    °¢¼º¹ÝÀÀ
  • autoimmune response
    ÀÚ°¡¸é¿ª¹ÝÀÀ
  • alerting response
    °¢¼º¹ÝÀÀ
  • anamnestic response
    ¸é¿ª±â¾ï¹ÝÀÀ
  • biologic response modifier
    »ý¹°ÇÐÀû¹ÝÀÀÁ¶ÀýÁ¦, »ýü¹ÝÀÀÁ¶Àý¹°Áú
  • biological response modifier
    »ý¹°ÇÐÀû¹ÝÀÀÁ¶ÀýÁ¦, »ýü¹ÝÀÀÁ¶Àý¹°Áú
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • resistance factor
    ³»¼ºÀÎÀÚ, °ßµõÀÎÀÚ
  • rheumatoid factor
    ·ù¸¶Æ¼½ºÀÎÀÚ
  • risk factor
    À§ÇèÀÎÀÚ
  • transforming growth factor
    Àüȯ¼ºÀåÀÎÀÚ
  • vascular endothelial growth factor
    Ç÷°ü³»ÇǼºÀåÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • serum urea nitrogen/creatinine ratio
    Ç÷û¿ä¼ÒÁú¼ÒÅ©·¹¾ÆÆ¼´Ñºñ
  • serum
    Ç÷û
  • serum separator
    Ç÷ûºÐ¸®±â
  • serum shock
    Ç÷û¼îÅ©
  • serum sickness
    Ç÷ûº´
  • serum typing
    Ç÷ûÇü°Ë»ç
  • specific serum
    ƯÀÌÇ÷û
  • standard serum
    ±âÁØÇ÷û
  • alerting response
    °¢¼º¹ÝÀÀ
  • anamnestic response
    (¢¡secondary immune response) ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • arousal response
    °¢¼º¹ÝÀÀ
  • autoimmune response
    ÀÚ°¡¸é¿ª¹ÝÀÀ
  • brainstem evoked response audiometry
    ³úÁÙ±âÀ¯¹ß¹ÝÀÀû·Â°Ë»ç
  • evoked response audiometry
    À¯¹ß¹ÝÀÀû·Â°Ë»ç
  • galvanic skin response audiometry
    ÇǺÎÀü±â¹ÝÀÀû·Â°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • placebo response
    Çö󼼺¸¹ÝÀÀ, À§<°¡>¾à¹ÝÀÀ.
  • positive placebo response
    Çö󼼺¸Ä¡·á È¿°ú.
  • pressure response
    À½¾Ð¹ÝÀÀ(ëåäâÚãëë).
  • primary antibody response
    ÀÏÂ÷Ç×ü¹ÝÀÀ
  • primary immune response
    ÀÏÂ÷¸é¿ª¹ÝÀÀ(¡­Øóæ¹Úãëë).
  • primary immune response
    ÀÏÂ÷¸é¿ª¹ÝÀÀ(¡­Øóæ¹Úãëë).
  • radiation response
    ¹æ»ç¼±¹ÝÀÀ
  • recruiting response
    µ¿¿ø¹ÝÀÀ(ÔÑê¬Úãëë).
  • Cattanis serum
    īŸ´Ï¾×.
  • Cattanis serum
    īŸ´Ï¾×.
  • Cattanis serum
    īŸ´Ï¾×.
  • Cherons serum
    »þ·Î¿ìÇ÷û.
  • Glutamine-oxaloacetic transaminase, serum
    ±Û·çŽ¿Á»ì¾Æ¼¼Æ®»ê Ʋ¶õ½º¾Æ¹Ì³ªÁ¦
  • Ham test=acidified serum test
    ÇÜ °Ë»ç, »ê¼ºÈ­Ç÷û¿ëÇ÷°Ë»ç
  • Loefflers coagulated serum medium
    ·ÚÇ÷¯ÀÀ°íÇ÷û»ç¸é¹èÁö
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • human serum immune globulin
    Àΰ£Ç÷û¸é¿ª±Û·ÎºÒ¸°.
  • human serum immune globulin
    Àΰ£Ç÷û¸é¿ª±Û·ÎºÒ¸°.
  • human serum immune globulin
    Àΰ£Ç÷û¸é¿ª±Û·ÎºÒ¸°.
  • human serum jaundice
    Àΰ£Ç÷ûȲ´Þ.
  • hyperimmune serum
    °íµµ¸é¿ªÇ÷û
  • icteric serum
    Ȳ´ÞÇ÷û
  • immune serum
    ¸é¿ªÇ÷û.
  • immune serum globulin
    ¸é¿ª Ç÷û ±Û·ÎºÒ¸°
  • immune serum globulin
    ¸é¿ªÇ÷û±Û·ÎºÒ¸°.
  • immune serum globulin transfusion
    ¸é¿ªÇ÷û±Û·ÎºÒ¸°¼öÇ÷
  • immunoglobulin G CSF/serum ratio
    ¸é¿ª±Û·ÎºÒ¸° G ³úô¼ö¾×/Ç÷û ºñ(À²)
  • inactivated serum
    ºñȰ¼ºÈ­Ç÷û.
  • inactive serum
    ºñȰ¼ºÇ÷û.
  • iodinated human serum albumin =IHSA
    ¿äµåÇ¥½ÄÀÎÇ÷û(¡­øöãÛìÑúìôè)¾ËºÎ¹Î.
  • lactescent serum
    À¯(»ó)È­Ç÷û
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • phosphatidylinositol response
    Æ÷½ºÆÄƼµô ´ëÀÀ(Óßëë)
  • PI response
    PI ´ëÀÀ(Óßëë)
  • pleiotypic response
    ´Ù¸é ´ëÀÀ(ÒýØüÓßëë)
  • primary immune response
    ÀÏÂ÷ ¸é¿ª´ëÀÀ(ìéó­Øóæ¹Óßëë)
  • primary response
    ÀÏÂ÷ ´ëÀÀ(ìéó­Óßëë)
  • SOS response
    SOS ´ëÀÀ(Óßëë)
  • staircase response
    °è´Ü ´ëÀÀ(Í­Ó«Óßëë)
  • stringent response
    ¾ö°Ý ´ëÀÀ(åñÌ«Óßëë)
  • tertiary response
    »ïÂ÷´ëÀÀ (ß²ó­Óßëë)
  • acetate-replacing factor
    ¾Æ¼¼Æ®»ê(ß«)ġȯ ÀÎÀÚ(öÇüµì×í­)
  • achromotrichia factor
    ¸ð¹ß»ö¼Ò°áÇÌÀÎÀÚ (Ù¾Û¥ßäáÈÌÀù¹ì×í­)
  • angiogenic factor
    Ç÷°üÇü¼ºÀÎÀÚ(úìηû¡à÷ì×í­)
  • animal protein factor
    µ¿¹°´Ü¹éÁúÀÎÀÚ(ÔÑÚªÓ±ÛÜòõì×í­)
  • anti-egg-white injury factor
    Ç׳­¹é ¼Õ»óÀÎÀÚ(ù÷ÑëÛÜáßß¿ì×í­)
  • anti-fatty-liver-factor
    Ç×Áö¹æ°£ÀÎÀÚ(ù÷ò·Û¸ÊÜì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
PAF paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl...
TF free thyroxine; tactile fremitus; tail flick [reflex]; temperature factor; testicular feminization; ...
LRSF lactating rat serum factor; liver regenerating serum factor
DF decapacitation factor; decontamination factor; deferoxamine; deficiency factor; defined flora [anima...
GRF gastrin-releasing factor; genetically related macrophage factor; gonadotropin-releasing factor; grow...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
APS Anti-platelet serum
ATS Anti-thymocyte serum
BCS Bovine Calf Serum
BSA Bovine Serum Albumin
BSAO Bovine serum amine oxidase
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • response
    ¹ÝÀÀ, ÀÀ´ä
    Àڱؿ¡ ÀÇÇÏ¿© ÀϾ´Â ÀÛ¿ëÀ̳ª ¿òÁ÷ÀÓ.
  • response to illness
    Áúº´¿¡ ´ëÇÑ ¹ÝÀÀ
  • sensitization response
    °¨ÀÛ ¹ÝÀÀ
  • stimulus response assessment
    ÀÚ±Ø ¹ÝÀÀ Æò°¡
  • thermal camera time response
    ¿­ Ä«¸Þ¶ó ½Ã°£ ¹ÝÀÀ
  • unconditioned response
    ¹«Á¶°Ç ¹ÝÀÀ
  • wide dynamic range response characteristics
    ±¤µ¿¹üÀ§ ¹ÝÀÀ Ư¡, ±¤µ¿Àû ¹üÀ§ ¹ÝÀÀ Ư¡
  • acute phase serum
    ±Þ¼º º´±â Ç÷û
  • acute serum sickness
    ±Þ¼º Ç÷ûº´
    Àü½Å¼º ¸é¿ªº¹ÇÕü ÁúȯÀÇ ÀüÇüÀûÀÎ ¿¹ÀÌ´Ù. Çѵ¿¾È Çǵ¿¼º ¸é¿ªÀ» À§ÇØ »ç¿ëµÈ ´Ù·®ÀÇ ÀÌÁ¾ Ç÷ûÀÇ Åõ¿©¿¡ µû¸¥ ÈÄÀ¯ÁõÀÌ´Ù.
  • Banzhaf serum
    ¹ÝÃ÷ÇÏÇÁ Ç÷û
    ³óÃà Ç×Æó¿°±Õ Ç÷û.
  • Bardel's serum
    ¹Ù¾Æµ¨ Ç÷û
  • blood serum
    Ç÷û
    1. Ç÷¾×ÀÌ ¿ÏÀüÈ÷ ÀÀ°íµÈ ´ÙÀ½ Ç÷¾×¿¡¼­ À¯¸®µÈ Åõ¸íÇÑ ¾×ü·Î, ÀÀ°í °úÁ¤¿¡ À־ Ç÷ÀåÀ¸·ÎºÎÅÍ ¼¶À¯¼Ò¿øÀÌ Á¦°ÅµÈ °Í. 2. Ç÷Àå¿¡¼­ ¼¶À¯¼Ò¿øÀ» Á¦°ÅÇÑ ³ª¸ÓÁö. »ýü¿¡¼­ äÃëÇÑ Ç÷¾×À» ½ÃÇè°ü¿¡ ³Ö¾î Á¶¿ëÈ÷ ¼¼¿öµÎ¸é ¸ÕÀú ÀÀ°íÇÏ¿© ÀÀÇ÷ÀÌ µÇ°í, À̰ÍÀÌ ¼öÃàÇÏ¿© ¾ÏÀû»öÀÇ µ¢¾î¸®ÀÎ Ç÷º´°ú ´ãȲ»öÀÇ Åõ¸íÇÑ ¾×üÀÎ Ç÷ûÀ¸·Î ³ª´©¾îÁø´Ù. Áï, Ç÷¾×¿¡¼­ À¯Çü ¼ººÐ ÀÌ¿ÜÀÇ ºÎºÐÀº Ç÷ÀåÀε¥, ÀÌ Ç÷Àå¿¡¼­ ¼¶À¯¼Ò¿ø
  • foreign serum
    ÀÌÁ¾ Ç÷û
  • horse serum
    ¸» Ç÷û
    ¸»ÀÇ Ç÷¾×¿¡¼­ ¾ò¾îÁö´Â Ç÷û.
  • human serum immune globulin
    Àΰ£ Ç÷û ¸é¿ª ±Û·ÎºÒ¸°
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
secondary antibody response An antibody made upon second (subsequent) exposure to an antigen, mostly of the class IgG.
(09 Oct 1997)
secondary immune response The response of the immune system to the second or subsequent occasion on which it encounters a specific antigen.
(18 Nov 1997)
humoral immune response <immunology> Those immune responses mediated by antibody.
(06 Mar 1998)
signal response coupling The cascade of processes by which an extracellular signal (typically a hormone or neurotransmitter) interacts with a receptor at the cell surface, causing a change in the level of a second messenger for example calcium or cyclic AMP) and ultimately effects a change in the cells functioning (for example: triggering glucose uptake or initiating cell division). Can also be applied to sensory signal transduction, for example of light at photoreceptors.
(18 Nov 1997)
hypersensitive response An active response of plant cells to pathogenic attack in which the cell undergoes rapid necrosis and dies. Associated with the production of phytoalexins, lignin and sometimes callose. The response is thought to prevent a potential pathogen from spreading through the tissues.
(18 Nov 1997)
sonomotor response Widespread myogenic potential evoked by click stimulation.
(05 Mar 2000)
sos response (genetics) An error-prone mechanism or set of functions for repairing damaged microbial DNA. Sos functions (a concept reputedly derived from the sos of the international distress signal) are involved in DNA repair and mutagenesis, in cell division inhibition, in recovery of normal physiological conditions after DNA repair, and possibly in cell death when DNA damage is extensive.
(12 Dec 1998)
stringent response The cellular response to amino acid starvation that reduces the amount of ribosomes to what can be employed under the nutrient conditions.
(05 Mar 2000)
depletion response Subnormal metabolic response to trauma in a person whose physiologic processes are already depressed by disease.
(05 Mar 2000)
dose-response curve This is a graph to show the relation between the dose of a drug or other chemical and the degree of response it produces, as measured by the percentage of the exposed population showing a defined, often quantal, effect.
(09 Oct 1997)
dose-response relationship Relationship in which a change in the amount, intensity, or duration of exposure is associated with a change in risk of a specified outcome.
(05 Mar 2000)
dose-response relationship, drug The relationship between the dose of an administered drug and the response of the organism to the drug.
(12 Dec 1998)
dose-response relationship, immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
(12 Dec 1998)
dose-response relationship, radiation The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation.
(12 Dec 1998)
immune response <immunology> Alteration in the reactivity of an organisms immune system in response to an antigen, in vertebrates, this may involve antibody production, induction of cell-mediated immunity, complement activation or development of immunological tolerance.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • pp factor
    Ç× Æç¶ó±×¶ó ÀÎÀÚ(Æç¶ó±×¶ó ¿¹¹æ¿¡ ¾²´Â ´ÏÄÚÆ¾»ê,´ÏÄÚÆ¾»ê¸¶À̵å)
  • prime factor
    ¼ÒÀμö
  • releasing factor
    È£¸£¸ó ¹æÃâÀÎÀÚ
  • rheumatoid factor
    ·ù¸ÓƼÁòÀÎÀÚ(¸¸¼º °üÀý ·ù¸ÓƼÁò ȯÀÚÀÇ ÀÚ±â Ç×ü)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á